Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

Australia–Japan laser a new step towards advanced defence manufacturing

Robots have a positive effect on employment and productivity: report

Hazer technology to be evaluated by major Japanese power utility

Researchers recover silver from end‍-‍of‍-‍life solar panels

Muting in practice: when safety becomes a vulnerability

Top 6 impacts of robots, revealed in IFR position paper

What food-grade compressed air actually means

Australian dairy sector mixes up its premium protein selection

Food ingredients specialist's solutions on show at Fi India 2026

Australian Grape & Wine CEO to depart end of September

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

When Connectivity Becomes Critical Care — Webinar

Unregistered doctor convicted after patient is hospitalised following medical procedure